James C. Wernz
- Oncology top 10%
- Cardiology and Cardiovascular Medicine top 10%
- Pathology and Forensic Medicine top 10%
- Pulmonary and Respiratory Medicine
- Physiology
- Co-authors
- Susan E. KrownCraig E. MetrokaJames L. SpeyerFranco M. MuggiaRonald H. BlumNeil DubinAnne Zeleniuch‐JacquottePeter Stecy
- Topics
- Cancer Treatment and Pharmacology (5 papers)Chemotherapy-induced cardiotoxicity and mitigation (4 papers)Chemotherapy-related skin toxicity (3 papers)
- Partner nations
- United StatesAustraliaPoland
In The Last Decade
James C. Wernz
11 papers receiving 547 citations
Peers
Comparison fields: 5 of 64
- Oncology 370
- Cardiology and Cardiovascular Medicine 232
- Pathology and Forensic Medicine 147
- Pulmonary and Respiratory Medicine 98
- Physiology 61
Countries citing papers authored by James C. Wernz
This map shows the geographic impact of James C. Wernz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James C. Wernz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James C. Wernz more than expected).
Fields of papers citing papers by James C. Wernz
This network shows the impact of papers produced by James C. Wernz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James C. Wernz. The network helps show where James C. Wernz may publish in the future.
Co-authorship network of co-authors of James C. Wernz
This figure shows the co-authorship network connecting the top 25 collaborators of James C. Wernz. A scholar is included among the top collaborators of James C. Wernz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James C. Wernz. James C. Wernz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 9 | |
| 3 | 1 | |
| 4 | 14 | |
| 5 | Kaposi's Sarcoma in the Acquired Immune Deficiency Syndrome: A Proposal for Uniform Evaluation, Response, and Staging Criteria | 173 |
| 6 | 281 | |
| 7 | Phase I trial of escalating dose doxorubicin administered concurrently with alpha 2-interferon. | 9 |
| 8 | 19 | |
| 9 | 8 | |
| 10 | 25 | |
| 11 | Phase I clinical trial of 9,10-anthracene dicarboxaldehyde (Bisantrene) administered in a five-day schedule. | 21 |
About James C. Wernz
James C. Wernz is a scholar working on Oncology, Dermatology and Reproductive Medicine, having authored 11 papers that have together received 561 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (5 papers), Chemotherapy-induced cardiotoxicity and mitigation (4 papers) and Chemotherapy-related skin toxicity (3 papers). The work is most often cited by research in Oncology (370 citations), Cardiology and Cardiovascular Medicine (232 citations) and Pathology and Forensic Medicine (147 citations). James C. Wernz has collaborated with scholars based in United States, Australia and Poland. Frequent co-authors include Susan E. Krown, Craig E. Metroka, James L. Speyer, Franco M. Muggia, Ronald H. Blum, Neil Dubin, Anne Zeleniuch‐Jacquotte, Peter Stecy, William Slater and Victor J. Ferrans. Their work appears in journals such as New England Journal of Medicine, Urology and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.